Editas Medicine (EDIT) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Editas Medicine is the larger company by market cap ($445.4 million vs $400.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | SCTX |
|---|---|---|
| Share price | $2.90 | $21.17 |
| Market cap | $445.38M | $400.78M |
| 1-day change | +2.11% | +10.09% |
| YTD return | +41.46% | — |
| 1-year return | -22.04% | — |
| 5-year return | -92.37% | — |
| EPS (TTM) | $-0.68 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $39.60 |
| 52-week low | $1.66 | $13.50 |
| Distance from 52-week high | -33.03% | -46.54% |
| Analyst consensus | buy | none |
| Avg. price target upside | +103.45% | +169.25% |
| Average volume | 2.51M | 358.12K |
| Shares outstanding | 153.58M | 18.93M |
| Employees | 87 | 82 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
EDIT vs SCTX FAQ
Which is bigger, Editas Medicine or Scribe Therapeutics?
Editas Medicine (EDIT) is larger, with a market capitalization of $445.38M compared with $400.78M for Scribe Therapeutics (SCTX).
Are Editas Medicine and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.